OCGNOcugen, Inc.vs its industry peers
A metric-by-metric comparison of Ocugen, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OCGN본 종목 | $344M#8 | — | — | 78.0x#7 | 8.8%#5 | -25.9%#9 | -1425.7%#6 | — | — | — | -12.9%#13 | — |
| KYTX | $427M#2 | — | 2.6x#12 | — | — | -26.5%#10 | — | -97.4%#13 | -107.1%#4 | — | 77.2%#5 | — |
| CCCC | $424M#3 | — | 1.7x#5 | 11.8x#5 | 1.0%#6 | 0.3%#6 | -320.5%#4 | -42.5%#8 | — | — | 1.3%#11 | — |
| CABA | $420M#4 | — | 2.0x#8 | — | — | -44.9%#13 | — | -79.7%#11 | — | — | 24.9%#9 | — |
| ARTV | $420M#5 | — | 1.2x#1 | — | -100.0%#8 | -28.3%#11 | — | -24.1%#5 | — | — | 262.7%#2 | — |
| EDIT | $418M#6 | — | 4.0x#13 | 10.3x#4 | 25.4%#3 | 32.5%#4 | -394.9%#5 | -152.0%#14 | — | — | -3.9%#12 | — |
| GRML | $477M#1 | — | 8.2x#14 | — | — | -71.6%#14 | — | -18.2%#4 | -14.6%#2 | — | -89.7%#16 | — |
| XFOR | $349M#7 | 2.5x#2 | 2.2x#10 | 10.0x#3 | 1273.2%#2 | -111.5%#16 | -247.4%#3 | -50.9%#10 | -582.0%#5 | — | 9.1%#10 | — |
| LXEO | $342M#9 | — | 1.5x#3 | 523.1x#8 | — | -1.7%#7 | -16706.0%#8 | -42.5%#9 | — | — | -19.9%#14 | — |
| IPSC | $340M#10 | — | 1.5x#4 | 3.1x#2 | 1556.8%#1 | 92.4%#3 | -15.8%#1 | -4.1%#2 | -9.3%#1 | — | 286.4%#1 | — |
| CMPX | $330M#11 | — | 2.0x#7 | — | -100.0%#8 | -34.7%#12 | — | -40.0%#7 | — | — | -49.2%#15 | — |
| AGEN | $325M#12 | 2.4x#1 | — | 2.8x#1 | 10.4%#4 | 98.7%#2 | -17.7%#2 | — | — | — | 61.5%#6 | — |
| IKT | $322M#13 | — | 2.1x#9 | — | -100.0%#8 | -75.4%#15 | — | -31.5%#6 | — | — | 48.1%#8 | — |
| SABS | $308M#14 | 14.1x#4 | 1.4x#2 | — | -100.0%#8 | 138.9%#1 | — | 6.2%#1 | — | — | 61.2%#7 | — |
| PALI | $293M#15 | 2.6x#3 | 2.4x#11 | — | — | -16.2%#8 | — | -13.8%#3 | — | — | 179.4%#3 | — |
| FATE | $291M#16 | — | 1.9x#6 | 43.8x#6 | -51.2%#7 | 26.8%#5 | -2222.4%#7 | -88.8%#12 | -102.3%#3 | — | 156.4%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice